Department of Gastroenterology and Hepatology, Erasmus MC, University Medical Center Rotterdam, 's Gravendijkwal 230, Rotterdam, The Netherlands.
J Gastroenterol. 2010 May;45(5):537-43. doi: 10.1007/s00535-009-0181-0. Epub 2009 Dec 22.
Gastrojejunostomy (GJJ) and stent placement are the most commonly used palliative treatments for malignant gastric outlet obstruction (GOO). In a recent randomized trial, stent placement was preferred in patients with a relatively short survival and GJJ in patients with a longer survival. As health economic aspects have only been studied in general terms, we estimated the cost of GJJ and that of stent placement in such patients.
In the SUSTENT study, patients were randomized to GJJ (n = 18) or stent placement (n = 21). Pancreatic cancer was the most common cause of GOO. We compared initial costs and costs during follow-up. For cost-effectiveness, the incremental cost-effectiveness ratio was calculated.
Food intake improved more rapidly after stent placement than after GJJ, but long-term relief of obstructive symptoms was better after GJJ. More major complications (P = 0.02) occurred and more reinterventions were performed (P < 0.01) after stent placement than after GJJ. Initial costs were higher for GJJ compared to stent placement (euro8315 vs. euro4820, P < 0.001). We found no difference in follow-up costs. Total costs per patient were higher for GJJ compared to stent placement (euro12433 vs. euro8819, P = 0.049). The incremental cost-effectiveness ratio of GJJ compared to stent placement was euro164 per extra day with a gastric outlet obstruction scoring system (GOOSS) >or=2 adjusted for survival.
Medical effects were better after GJJ, although GJJ had higher total costs. Since the cost difference between the two treatments was only small, cost should not play a predominant role when deciding on the type of treatment assigned to patients with malignant GOO (ISRCTN 06702358).
胃空肠吻合术(GJJ)和支架置入术是治疗恶性胃出口梗阻(GOO)最常用的姑息性治疗方法。在最近的一项随机试验中,支架置入术适用于生存期相对较短的患者,而胃空肠吻合术适用于生存期较长的患者。由于健康经济学方面仅进行了一般性研究,我们估算了此类患者中 GJJ 和支架置入术的成本。
在 SUSTENT 研究中,患者被随机分为 GJJ 组(n = 18)或支架置入组(n = 21)。胰腺癌是 GOO 最常见的病因。我们比较了初始成本和随访期间的成本。对于成本效益,计算了增量成本效益比。
支架置入术后,患者的进食改善速度快于 GJJ,但 GJJ 后梗阻症状的长期缓解效果更好。支架置入术后发生更多的主要并发症(P = 0.02),且需要更多的再介入治疗(P < 0.01)。与支架置入术相比,GJJ 的初始成本更高(欧元 8315 比欧元 4820,P < 0.001)。我们未发现随访成本存在差异。与支架置入术相比,GJJ 每位患者的总成本更高(欧元 12433 比欧元 8819,P = 0.049)。调整生存后,GJJ 相对于支架置入术的增量成本效益比为每天增加 164 欧元,用于评估胃出口梗阻评分系统(GOOSS)>或=2。
尽管 GJJ 的总费用较高,但 GJJ 的治疗效果更好。由于两种治疗方法的成本差异较小,因此在为恶性 GOO 患者选择治疗方法时,成本不应起主导作用(ISRCTN 06702358)。